

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics (P&T) Committee

Thursday, June 18, 2020, 6:00-8:00 PM

Santa Clara Family Health Plan, Boardroom

6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference

(669) 900-6833

Meeting ID: 991 6011 6046

Password: SCFHP2020

AGENDA

1. Roll Call / Establish Quorum	Dr. Lin	6:00	5 min
2. Public Comment Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes.	Dr. Lin	6:05	5 min
3. Open Meeting Minutes Review Santa Clara Family Health Plan (SCFHP) 1Q2020 P&T Open Minutes Possible Action: Approve SCFHP P&T Open Minutes	Dr. Lin	6:10	2 min
4. Standing Agenda Items			
a. Chief Medical Officer Health Plan Updates	Dr. Nakahira	6:12	5 min
b. Medi-Cal Rx Update	Dr. Huynh	6:17	3 min
c. Plan/Global Medi-Cal Drug Use Review	Dr. Otomo	6:20	5 min
i. Global Medi-Cal DUR Board Activities			
ii. Drug Use Evaluation			
d. Emergency Supply Report	Dr. Nguyen	6:25	5 min
i. 2018 4 th Quarter Report			
ii. 2019 1 st Quarter Report			
Adjourn to Closed Session <i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i>			
5. Closed Meeting Minutes Review SCFHP 1Q2020 P&T Closed Session Minutes Possible Action: Approve SCFHP P&T Closed Session Minutes	Dr. Lin	6:30	2 min
6. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:32	2 min
b. Pharmacy Dashboard	Dr. Otomo	6:34	2 min
c. Drug Utilization & Spend	Dr. McCarty	6:36	5 min

7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria	Dr. McCarty	6:41	2 min
<ul style="list-style-type: none"> a. Pharmacy Benefit Manager 1Q2020 P&T Minutes b. Pharmacy Benefit Manager 2Q2020 P&T Part D Actions Possible Action: Approve MedImpact Minutes & Actions			
8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal & Prior Authorization Criteria	Dr. McCarty	6:43	3 min
<ul style="list-style-type: none"> a. Old Business/Follow-Up <ul style="list-style-type: none"> i. Vascepa (icosapent ethyl) 			
<ul style="list-style-type: none"> b. Formulary Modifications Possible Action: Approve Recommendations	Dr. Otomo	6:46	5 min
<ul style="list-style-type: none"> c. Fee-for-Service Contract Drug List Comparability Possible Action: Approve Recommendations	Dr. McCarty	6:51	5 min
<ul style="list-style-type: none"> d. Prior Authorization Criteria 	Dr. Nguyen	6:56	15 min
<ul style="list-style-type: none"> <ul style="list-style-type: none"> i. <u>New or Revised Criteria</u> 			
<ul style="list-style-type: none"> <ul style="list-style-type: none"> <ul style="list-style-type: none"> 1. Oncology 2. Hepatitis C Policy 3. Epclusa 4. Mavyret 5. Enablex 6. Rhopressa 7. Dovonex 8. Androgel 9. Elmiron 10. Lysteda 11. Provigil 12. Symlin 13. Tymlos 14. Mycobutin 15. Amitiza 16. Restasis 17. Marinol 18. Nebupent 			
<ul style="list-style-type: none"> <ul style="list-style-type: none"> ii. <u>Annual Review</u> 			
<ul style="list-style-type: none"> <ul style="list-style-type: none"> <ul style="list-style-type: none"> 1. Reauthorization 2. Non-Formulary - Oral Liquids 3. Terminally Ill – Pain Medications 4. Diabetic Supplies (Blood glucose meter, test strips, & lancets) 5. Ciprodex 6. Exelon 7. Hycet 8. Intron A 9. Lovaza 10. Makena 11. Malarone 12. Revatio 13. Santyl 14. Sporanox 15. Viroptic 16. Xenazine 17. Letairis 			
Possible Action: Approve criteria			

9. New Drugs and Class Review

a. Chewable Birth Control Pills	Dr. Huynh	7:11	5 min
b. Diabetes Update			
i. Trulicity – Cardiovascular Outcomes	Dr. McCarty	7:16	10 min
ii. Continuous Glucose Monitor (CGM)			
iii. Farxiga – Heart Failure	Dr. Xia	7:26	10 min
c. Thyroid Eye Disease – Tepezza	Dr. McCarty	7:36	20 min
d. New Derivatives, Formulations, Combinations			
e. New/Expanded Indications			
Possible Action: Approve recommendations			
f. <u>Informational Only</u>			
i. Mycapssa - Acromegaly			
ii. Obeticholic acid – Non-alcoholic steatohepatitis			
iii. Fintepla - Dravet Syndrome			
iv. Ofatumumab - Multiple Sclerosis			
v. Opicapone - Parkinson's Disease			
vi. Risdiplam - Spinal Muscular Atrophy			
vii. Ayvakit, Tazverik, Sarclisa – Oncology			
viii. Scenesse – Erythropoietic protoporphyria			

Reconvene in Open Session

10. Discussion Items

- a. New and Generic Pipeline

Dr. McCarty 7:56 4 min

11. Adjournment

Next meeting Thursday, September 17, 2020

Dr. Lin 8:00

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com